Clinical Trial: Trial of Gemcitabine, Cisplatin, and Ifosfamide in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors

Study Status: Terminated
Recruit Status: Unknown status
Study Type: Interventional

Official Title: A Prospective Multicenter Phase II Trial of Gemcitabine, Cisplatin, and Ifosfamide (GIP) in Patients With Relapsed Non-Seminomatous Germ-Cell Tumors (NSGCT) and a Predicte

Brief Summary: This is a prospective multicenter phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed non-seminomatous germ-cell tumors (NSGCT) and a predicted favorable prognosis.

Detailed Summary:
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Current Primary Outcome: Complete response rate

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Toxicity
  • Progression free survival
  • Overall survival


Original Secondary Outcome:

  • Toxicity
  • Progression
  • Free survival
  • Overall survival


Information By: Gustave Roussy, Cancer Campus, Grand Paris

Dates:
Date Received: August 3, 2005
Date Started: December 2004
Date Completion:
Last Updated: September 7, 2006
Last Verified: September 2006